Abstract
Stroke is a major cause of death and disability worldwide. The resulting burden on society grows with the increase in the incidence of stroke. The term brain attack was introduced to describe the acute presentation of stroke and emphasize the need for urgent action to remedy the situation. Though a large number of therapeutic agents, like thrombolytics, NMDA receptor antagonists, calcium channel blockers and antioxidants, have been used or are being evaluated, there is still a large gap between the benefits of these agents and the properties of an ideal drug for stroke. So far, only thrombolysis with rtPA within a 3-hour time window has been shown to improve the outcome of patients with ischemic stroke. Understanding the mechanisms of injury and neuroprotection in these diseases is important to target news sites for treating ischemia. Better evaluation of the drugs and increased similarity between the results of animal experimentation and in the clinical setting requires critical assessment of the selection of animal models and the parameters to be evaluated. Our laboratory has employed a rat embolic stroke model to investigate the combination of rtPA with citicoline as compared to monotherapy alone and investigated whether neuroprotection should be provided before or after thrombolysis in order to achieve a greater reduction of ischemic brain damage.
References
1.
Heiss W, Graft R: The ischemic penumbra. Curr Opin Neurol 1994;7:11–19.
2.
Astrup J, Siesjö B, Symon L: Thresholds in cerebral ischemia: the ischemic penumbra. Stroke 1981;12:723–725.
3.
Baron J, von Kummer R, del Zoppo G: Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke 1995;26:2219–2221.
4.
Fisher M: Characterizing the target of acute stroke therapy. Stroke 1997;28:866–872.
5.
Massieu l, Thedinga K, McVey M, Fagg G: A comparative analysis of the neuroprotective properties of competitive and uncompetitive N-methyl-aspartate receptor antagonist in vivo: implications for the process of excitotoxic degeneration and its therapy. Neuroscience 1993;55:883–892.
6.
Davis S, Lees K, Albers G, Diener H, Markabi S, Karlsson G, Norris J: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347–354.
7.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
8.
Brinker G, Franke C, Hoehn M, Uhlenkuken U, Hossmann K: Thrombolysis of cerebral clot embolism in rat: effect of treatment delay. Neuroreport 1999;10:3269–3272.
9.
Grotta J: The current status of neuronal protective therapy: why have all neuronal protective drugs worked in animals but none so far in stroke patients? Cerebrovasc Dis 1994;4:115–120.
10.
Del Zoppo G, Wagner S, Tagaya M: Trends and future developments in the pharmacological treatment of acute ischaemic stroke. Drugs 1997;54:9–38.
11.
Lees K: Does neuroprotection improve stroke outcome? Lancet 1998;351:1447–1448.
12.
Choi D: Antagonizing excitotoxicity: a therapeutic strategy for stroke? Mt Sinai J Med 1998;65:133–138.
13.
Kontos H: Oxygen radicals in cerebral vascular injury. Circ Res 1985;57:508–516.
14.
Chan P: Role of oxidants in ischemic brain damage. Stroke 1996;27:1124–1129.
15.
Chopp M, Zhang Z: Anti-adhesion molecule and nitric oxide protection strategies in ischemic stroke. Curr Opinion Neurol 1996;9; 68–72.
16.
Barinaga M: Stroke-damaged neurons may commit cellular suicide. Science 1998;281:1302–1304.
17.
Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gómez-Isla T, Hyman B, Moskowitz M: Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 1998;18:238–247.
18.
Alonso de Leciñana M, Díez Tejedor E, Carceller F: Cerebral ischemia: from animal studies to clinical practice. Should the methods be reviewed? Cerebrovasc Dis 2001;11(suppl 1):20–30.
19.
Fisher M, Brott T: Emerging therapies for acute ischemic stroke. New therapies on trial. Stroke 2003;34:359–361.
20.
Tamura A, Graham D, McCulloch J, Teasdale G: Focal cerebral ischemia in the rat. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab 1981;1:53–60.
21.
Roda J, Carceller F, Díez Tejedor E, Avendaño C: Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia. Stroke 1995;26:1888–1892.
22.
Koizumi J, Yoshida Y, Nakazawa T, Oneda G: Experimental studies of ischemic brain edema. A new experimental model of cerebral embolism in rats which recirculation can be reintroduced in the ischemic area. Jpn J Stroke 1986;8:1–8.
23.
Overgaard K, Sereghy T, Boysen G, Pedersen H, Hoyer S, Diemer N: A rat model of reproducible cerebral infarction using thrombotic blood clot emboli. J Cereb Blood Flow Metab 1992;12:484–490.
24.
Alonso de Leciñana M, Díez Tejedor E, Carceller F, Vega A, Roda J: Advantages of associate inhibitors of ischemia reperfusion injury to intravenous thrombolysis for treatment of focal cerebral ischemia. Description of an experimental model. Rev Neurol 1996;24:207–213.
25.
NINDS t-PA Stroke Study Group: Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109–2118.
26.
Katzan I, Furlan A, Lloyd L, et al: Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. JAMA 2000;283:1151–1158.
27.
Heo J, Kim S, Lee K, Kim E, Chu C, Nam J: Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003;34:48–50.
28.
Montaner J, Molina C, Monasterio J, et al: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598–603.
29.
Adams H, Adams R, Del Zoppo G, Goldstein L: Guidelines for the early management of patients with ischemic stroke. 2005 Guidelines Update. A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005;36:916–921.
30.
Toni D, Chamorro A, Kaste M, Lees K, Wahlgren N, Hacke W for the EUSI Executive Committee and the EUSI Writing Committee. Cerebrovasc Dis 2004;17(suppl 2):30–46.
31.
Lee J, Zipfel G, Choi D: The changing landscape of ischaemic brain injury mechanisms. Nature 1999;399(suppl): A7–A14.
32.
Fisher M, Bogousslavsky J: Further evolution toward effective therapy for acute ischemic stroke. JAMA 1998;279:1298–1303.
33.
Martinez-Vila E, Sieira P: Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 2001;11:60–70.
34.
Gamman R, Sherman D: ECCO 2000 Investigators. ECCO 2000 study of citicoline for treatment of acute ischemic stroke: final results. Stroke 2000;31:278A.
35.
Dávalos A, Castillo J, Ðlvarez-Sabín J, Secades J, Mercadal J, López S, Cobo E, Warach S, Sherman D, Clark W, Lozano R: Oral citicoline in acute ischemic stroke. An individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850–2857.
36.
Stroke Therapy Academic Industry Roundtable II: Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598–1606.
37.
Lindsberg P, Roine R, Tatlisumak T, Sairanen T, Kaste M: The future of stroke treatment. Neurol Clin 2000;18:495–510.
38.
Kaste M: Thrombolysis in ischaemic stroke: present and future: role of combined therapy. Cerebrovasc Dis 2001;11(suppl 1):55–59.
39.
Dawson D, Wadsworth G, Palmer A: A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res 2001;892:344–350.
40.
Andersen M, Overgaard K, Meden P, Boysen G, Choi S: Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 1999;30:1464–1471.
41.
Meden P, Overgaard K, Sereghy T, Boysen G: Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Neurol Sci 1993;119:209–216.
42.
Zivin J, Mazzarella V: Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 1991;48:1235–1238.
43.
Zhang R, Zhang Z, Chopp M: Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology 1999;52:273–279.
44.
Yang Y, Li Q, Shuaib A: Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate. Neuropharmacology 2000;39:881–888.
45.
Lekieffre D, Benavides J, Scatton B, Nowicki J: Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model. Brain Res 1997;776:88–95.
46.
Meden P, Overgaard K, Pedersen H, Boysen G: Effect of early treatment with tirilazad (U7400F) combined with delayed thrombolytic therapy in rat embolic stroke. Cerebrovasc Dis 1996;6:141–148.
47.
Overgaard K, Sereghy T, Pedersen H, Boysen G: Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke. Neurol Res 1993;15:344–349.
48.
Grotta J: The Combination Therapy Stroke Trial Investigators. Combination therapy stroke trial: recombinant tissue plasminogen activator with/ without lubeluzole. Cerebrovasc Dis 2001;12:258–263.
49.
Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, Nordlund A, Odergren T: The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology 2001;57:1199–1205.
50.
Tovarelli G, DeMedio G, Dorman R, Piccinin G, Horrocks L, Porcellati G: Effects of cytidine diphosphate choline (CDP-choline) on ischemia-induced alteration of brain lipid in the gerbil. Neurochem Res 1981;6:821–833.
51.
Secades J: CDP-choline: updated pharmacological and clinical review. Methods Find Exp Clin Pharmacol 2002;24(suppl 2):1–56.
52.
Krupinski J, Ferrer I, Barrachina M, Secades J, Mercadal J, Lozano R: CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology 2002;42:846–854.
53.
Sereghy T, Overgaard K, Boysen G: Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 1993;24:1702–1708.
54.
Shuaib A, Yang Y, Li O: Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp Neurol 2000;161:733–739.
55.
Alonso de Leciñana M, Gutiérrez M, Roda JM, Carceller F, Díez Tejedor E: Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Neurol Sci 2006 (in press).
56.
Gutiérrez M: Tratamiento del infarto cerebral mediante trombolisis i.v. y neuroproteción aisladas o combinadas en isquemia cerebral focal en rata; thesis, Universidad Autónoma Madrid, Madrid 2005.
57.
Díez Tejedor E, Gutierrez M, Carceller F, Roda JM, Alonso de Leciñana M: Treatment with reperfusion and neuroprotection with low and high dose of citicoline in an experimental model of focal cerebral ischemia. Which is the best? Cerebrovasc Dis 2004;17(suppl 5):67.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
